Business Wire

LR Health & Beauty invests in the support of its sales partners

14.5.2019 14:18:00 EEST | Business Wire | Press release

Share

LR Health & Beauty continuously invests in the development of modern sales concepts which enable the partners to successfully set up and expand their businesses. The company has now launched the innovative tool "LR MyOffice" to support sales partners with their work in the digital LR world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005504/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LR Health & Beauty invests in the support of its sales partners (Photo: Business Wire)

Transparent, simple and compatible with all devices

In cooperation with the American software provider Exigo, the direct sales company from Ahlen was able to take digitalisation to the next level. Thanks to "LR MyOffice" sales partners can get information on all relevant business figures and activities at a glance – the data is updated around the clock. What turnover have I achieved thus far this month? How are my team members developing? Are there persons in my team who soon celebrate their birthday or jubilee, whom I can congratulate? "LR MyOffice" has the answers and works as a personal assistant. "The programme helps LR partners to better understand their business figures and to control their business activities", says Andreas Friesch, CEO and management spokesman of LR. Furthermore, the tool runs on all terminal devices – not only on the PC at home but also on tablets and smartphones.

Clear activity orientation for new partners and professionals

The special feature of "LR MyOffice" is that every partner sees at first glance what he and his team members have to do to reach the next bonus or career level. Thanks to easy application, even novices manage the tool with ease and are able to quickly manage their LR business independently. The tool box enables profs to exploit opportunities with regard to structure and daily routine even more efficiently. "We were very pleased to partner with LR to leverage our technical expertise and platform, to create the new tool for LR's partners", says Ed Jarrin, President of Exigo.

Positive feedback in the prelaunch phase

The prelaunch phase started last February – from 14 May, the tool will be available for all LR sales partners. "From my point of view, 'LR MyOffice' has already proved its worth. The partners who used the tool in the prelaunch phase are simply impressed", says Friesch contently. In the course of the next few months, new functions will be added to the programme.

LR Health & Beauty

Under the motto “More quality for your life“, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in around 28 countries. The range includes care and decorative cosmetics, dietary supplements and perfumes. LR Health & Beauty attaches great importance to the processing of premium raw materials. As most articles are manufactured at the Ahlen site, the company stands for top products "made in Germany". The processing of Aloe Vera has been one of the core competencies of LR Health & Beauty for more than 15 years. Only the valuable inside of the leaf is used for the products. With a volume of 12,000 tonnes of Aloe Vera leafs per year, LR is among the world’s largest manufacturers of Aloe Vera products. In Ahlen, the company has established the most modern Aloe Vera production site for Aloe Vera Drinking Gels in Europe. With 1,100 employees as well as thousands of registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. LR's strong market position is based above all on a high-quality product range and an attractive bonus and training plan which is unsurpassed in the industry. LR also established the LR Global Kids Fund e. V. which provides efficient and unbureaucratic support for deprived children and their families in many different countries around the world in cooperation with local institutions.

Exigo

Exigo is the leading global technology provider in the direct selling industry. Exigo supports 100 direct selling companies around the world, which include 12 of the 2019 DSN Global Top 100 direct sales companies. Exigo’s global clients operate in over 120 countries, 40 currencies and 30 languages.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LR Health & Beauty
Almut Kellermeyer
Head of PR / Public Affairs
Tel: +49 2382 7060-114
Email: a.kellermeyer@LRworld.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye